Market capitalization | $256.23m |
Enterprise Value | $106.51m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.51 |
P/S ratio (TTM) P/S ratio | 3.62 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -42.30% |
Revenue (TTM) Revenue | $70.72m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
6 Analysts have issued a Adc Therapeutics SA forecast:
6 Analysts have issued a Adc Therapeutics SA forecast:
Sep '24 |
+/-
%
|
||
Revenue | 71 71 |
42%
42%
|
|
Gross Profit | 65 65 |
43%
43%
|
|
EBITDA | -133 -133 |
4%
4%
|
EBIT (Operating Income) EBIT | -137 -137 |
4%
4%
|
Net Profit | -212 -212 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Head office | Switzerland |
CEO | Ameet Mallik |
Employees | 162 |
Founded | 2011 |
Website | www.adctherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.